Sarepta Therapeutics (SRPT) Cost of Revenue (2017 - 2026)

Sarepta Therapeutics' Cost of Revenue history runs 10 years deep, the most recent figure standing at $108.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue fell 20.93% year-over-year to $108.8 million; the TTM figure through Mar 2026 stood at $810.8 million (up 99.66% YoY), while the FY2025 annual figure was $839.6 million, up 163.12% from the prior year.
• Cost of Revenue was $108.8 million for Q1 2026 at Sarepta Therapeutics, down from $398.7 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $398.7 million in Q4 2025 to a low of $30.8 million in Q4 2022.
• Historically, Cost of Revenue has averaged $91.6 million across 5 years, with a median of $44.5 million in 2024.
• The sharpest annual moves came in 2025 and 2026: Cost of Revenue jumped 242.48% in 2025, then dropped 20.93% in 2026.
• A 5-year view of Cost of Revenue shows it stood at $30.8 million in 2022, then soared by 43.43% to $44.2 million in 2023, then soared by 199.49% to $132.3 million in 2024, then jumped by 201.36% to $398.7 million in 2025, then tumbled by 72.72% to $108.8 million in 2026.
• The last three Cost of Revenue figures came in at $108.8 million (Q1 2026), $398.7 million (Q4 2025), and $150.8 million (Q3 2025), per Business Quant data.